Clinical Trial Update: Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial of guanfacine extended release for aggression and self-injury in Prader-Willi Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• Guanfacine Extended Release (guanfacine)

Snippet

Sponsor: NYU Langone Health | Conditions: Prader-Willi Syndrome | Phase 4 | Status: WITHDRAWN